Replies to post #1569 on GTC Biotherapeutics (fka GTCB)

[w_wabbit]

That would be precisely my point. GTCB was not only trading at $50 during the bubble, it was still trading at $4+ at the depths of the market lows in 2001-2002, and later.

Now it has an approved drug and is constantly losing ground, worth more or less a buck. That's right, $1. Or 75% less than just three years ago when BK was still a possible danger.

Are you telling me you are happy with that? What's the incentive to invest if Atryn approval can't move the stock? Moral satisfaction?